Welcome to the international HTA database

Showing [23371 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2013	Malaysian Health Technology Assessment (MaHTAS)	Colostrum for cosmetic purpose and cell regeneration
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Inflectra (infliximab biosimilar) for psoriatic arthritis
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Botulinum toxin type A (Botox®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Probiotics in infants: clinical effectiveness, safety and guidelines
2013	Norwegian Knowledge Centre for the Health Services (NOKC)	Obstetric consequences of female genital mutilation/cutting (FGM/C)
2013	Malaysian Health Technology Assessment (MaHTAS)	Chlorthalidone for hypertensive patients
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Odanacatib for male osteoporosis – first and second line
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Etanercept (Enbrel®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Rasburicase for adults with acute tumor lysis syndrome: a review of clinical and cost effectiveness and safety
2013	Norwegian Knowledge Centre for the Health Services (NOKC)	[Effects of interventions for reducing emergency admissions from nursing homes]
2013	Malaysian Health Technology Assessment (MaHTAS)	Avemar granulate as dietary food / special purpose food for cancer
2013	NIHR Horizon Scanning Centre (NIHR HSC)	NeuroAD™ for mild and moderate Alzheimer's Disease
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Saxagliptin (Onglyza®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Patient lifts and transfer equipment for preventing pressure ulcers: a review of clinical and cost-effectiveness and guidelines
2013	Malaysian Health Technology Assessment (MaHTAS)	Water birth
2013	New Zealand National Health Committee (NHC)	Renal denervation – technology note
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Bucelipase-alfa (Kiobrina) for pre-term infants
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Lixisenatide (Lyxumia®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Esophageal doppler ultrasound-based cardiac output monitoring for adults undergoing surgery: a review of clinical and cost-effectiveness
2013	New Zealand National Health Committee (NHC)	Percutaneous interventions for mitral regurgitation - technology Note
2013	NIHR Horizon Scanning Centre (NIHR HSC)	ICES13 for stress urinary incontinence in women - second line
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Sodium phenylbutyrate (Pheburane®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Blood glucose monitors and test strips: a review of the comparative clinical evidence and cost-effectiveness — an update
2013	New Zealand National Health Committee (NHC)	Left atrial appendage – technology note
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Eculizumab (Soliris) for Shiga-Toxin producing Escherichia coli Haemolytic-Uraemic Syndrome – first line
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Etravirine (Intelence®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Drug therapies for immunosuppression in adult patients following islet cell transplantation for the treatment of diabetes: clinical and cost-effectiveness
2013	New Zealand National Health Committee (NHC)	New and emerging cardiac technologies in Australian and New Zealand public health service over the next decade
2013	NIHR Horizon Scanning Centre (NIHR HSC)	NephroCheck® Test for assessing risk of acute kidney injury
2013	Andalusian Health Technology Assessment Area (AETSA)	[Efficacy and safety of ventricular assist devices]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	JC virus antibody testing for patients with MS: a review of the diagnostic accuracy and guidelines
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Treatment by clinical psychologists; Literature overview on training, methods of treatment and areas of application]
2013	Malaysian Health Technology Assessment (MaHTAS)	Transcranial Doppler (TCD) ultrasound and cerebral computed tomography perfusion (CTP) for aneurysmal subarachnoid haemorrhage (SAH)
2013	New Zealand National Health Committee (NHC)	Ventilation tubes: an opportunity for better targeting - technology note
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Nintedanib for idiopathic pulmonary fibrosis – first line
2013	Andalusian Health Technology Assessment Area (AETSA)	[A review of indications for ventricular assist device therapy]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatment of patients with multiple sclerosis: a review of guidelines
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Hadron therapy: proton and carbon ion therapy - a review of clinical evidence of efficacy, ongoing research and reimbursement]
2013	NIHR Public Health Research (PHR) programme	Systematic review of the effects of schools and school environment interventions on health: evidence mapping and synthesis
2013	NIHR Health Technology Assessment programme	Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Ustekinumab (Stelara) for plaque psoriasis in adolescents
2013	Andalusian Health Technology Assessment Area (AETSA)	[Efficacy, safety and efficiency of computed tomographic colonography vs. colonoscopy as colorectal cancer screening test]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Tinzaparin versus dalteparin or enoxaparin for the treatment of venous thromboembolism in adults: safety and guidelines
2013	NIHR Public Health Research (PHR) programme	Systematic review of the effects of schools and school environment interventions on health: evidence mapping and synthesis
2013	NIHR Health Technology Assessment programme	A cluster randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of classroom-based cognitive-behavioural therapy (CBT) in reducing symptoms of depression in high-risk adolescents
2013	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Music therapy in palliative setting]
2013	Andalusian Health Technology Assessment Area (AETSA)	[Efficacy, safety and efficiency of electrical spinal cord stimulation for the treatment of chronic musculoskeletal pain]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Techniques to improve the use of diagnostic laboratory test ordering: clinical evidence
2013	NIHR Public Health Research (PHR) programme	Reducing alcohol-related harm in disadvantaged men: development and feasibility assessment of a brief intervention delivered by mobile telephone
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Pazopanib (Votrient) for renal cell carcinoma – adjuvant therapy
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Antibiotic prophylaxis for patients with cardiac or orthopedic implants undergoing dental procedures: a review of the clinical effectiveness and guidelines
2013	NIHR Public Health Research (PHR) programme	Community engagement to reduce inequalities in health: a systematic review, meta-analysis and economic analysis
2013	NIHR Health Technology Assessment programme	A cluster randomised controlled trial of a manualised cognitive behavioural anger management intervention delivered by supervised lay therapists to people with intellectual disabilities
2013	NIHR Health Technology Assessment programme	A systematic review and cost-effectiveness analysis of specialist services and adrenaline auto-injectors in anaphylaxis
2013	National Evidence-based Healthcare Collaborating Agency (NECA)	[Cost-effectiveness of human papillomavirus vaccination in South Korea]
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Ponatinib (Iclusig) for chronic myeloid leukaemia
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Biologic response modifier agents as first-line treatment for patients with rheumatoid arthritis: a review of the clinical efficacy, cost-effectiveness and guidelines
2013	NIHR Health Technology Assessment programme	Adjunctive colposcopy technologies for examination of the uterine cervix - DySIS, LuViva Advanced Cervical Scan and Niris Imaging System: a systematic review and economic evaluation
2013	National Evidence-based Healthcare Collaborating Agency (NECA)	[Prescription patterns and safety of benzodiazepines in Korea]
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Ramucirumab monotherapy for advanced gastric cancer and gastro-oesophageal junction adenocarcinoma – after prior chemotherapy
2013	NIHR Health Technology Assessment programme	Pixantrone monotherapy for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Bone morphogenetic proteins for use in spinal surgery and long bone trauma surgery: a review of the clinical effectiveness and safety
2013	NIHR Health Technology Assessment programme	Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Carfilzomib for relapsed and/or refractory multiple myeloma
2013	NIHR Health Technology Assessment programme	Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small cell lung cancer
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Fecal management systems for hospitalized adult patients: comparative clinical effectiveness and safety
2013	The Swedish Council on Health Technology Assessment (SBU)	[Internet-based psychological treatment for anxiety and mood disorders]
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Lenalidomide (Revlimid) for mantle cell lymphoma
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Osteostimulative bone graft substitutes or demineralized bone matrix preparations for use in spinal Surgery and long bone trauma surgery: clinical effectiveness and safety
2013	NIHR Health Technology Assessment programme	Risk Adjustment In Neurocritical care (RAIN) - prospective validation of risk prediction models for adult patients with acute traumatic brain injury to use to evaluate the optimum location and comparative costs of neurocritical care: a cohort study
2013	NIHR Health Technology Assessment programme	Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Liposomal cisplatin (Lipoplatin) in combination with fluorouracil for head and neck cancer
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Fusidic acid for ophthalmic infections: a review of clinical and cost effectiveness and safety
2013	The Swedish Council on Health Technology Assessment (SBU)	[Dietary treatment of obesity]
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Nivolumab for non-small cell lung cancer – second line
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	The timing of prophylactic antibiotics for surgery: a review of the clinical Evidence
2013	NIHR Health Technology Assessment programme	Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Paclitaxel polyglutamate (Opaxio) in combination with temozolamide and radiotherapy for glioblastoma – first line
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Computed tomography guided versus ultrasound guided renal biopsy: comparative evidence
2013	NIHR Horizon Scanning Centre (NIHR HSC)	PROSTVAC Immunotherapy for chemotherapy-naïve hormone-relapsed prostate cancer
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Prioritizing patients undergoing non-urgent, medically necessary cosmetic surgical procedures: clinical evidence and guidelines
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Lymphoseek® for lymphatic mapping and sentinel lymph node location in breast cancer, head and neck cancer and melanoma
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Codeine compared with other opioids for pain relief in pediatric patients: comparative clinical effectiveness, safety, and guidelines
2013	NIHR Horizon Scanning Centre (NIHR HSC)	CardioMEMs HF System for heart failure
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Meperidine to relieve shivering or bladder spasm: clinical effectiveness
2013	NIHR Horizon Scanning Centre (NIHR HSC)	C-Pulse® Heart assist system for heart failure
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Inhaled tobramycin versus intravenous tobramycin for patients with cystic fibrosis: a review of the clinical effectiveness, cost effectiveness, and guidelines
2013	The Swedish Council on Health Technology Assessment (SBU)	[Occupational exposures and sleep disturbances]
2013	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Prevention of nephropathy by iodinated contrast media during a radiological intervention]
2013	NIHR Horizon Scanning Centre (NIHR HSC)	BioMimics 3D™ stent for peripheral artery disease
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Antibiotics for the prevention of post-cesarean section complications: clinical evidence and safety
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Revivent™ for heart failure with left ventricular scar
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Optimal timing and frequency of follow-up care for patients receiving at-home supplemental oxygen: clinical evidence and guidelines
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Liraglutide for obesity or overweight in patients with associated co-morbidities
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Wrist sphygmomanometry versus upper arm sphygmomanometry: clinical effectiveness and guidelines
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Hybrid operating room]
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Macula Risk PGx test for dry age-related macular degeneration
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	The use of dental crowns for vital and endodontically treated teeth: a review of the clinical and cost-effectiveness and guidelines
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Reorientation of the Austrian parent-child preventive care programme - Part IX: Evidence-based screening guidelines for pregnant women and children (0 – 6 yrs.)]